At the Technology and Heart Failure Therapeutics (THT) conference in Boston, CardiaMetrics presented its first scientific results and engaged with clinicians, researchers, and industry leaders working to transform heart failure management.

Beyond the scientific sessions, the discussions across the conference highlighted a clear shift in the field: remote monitoring is no longer only about collecting physiological data — it is about making that data clinically actionable.

The Limits of Data-Heavy Wearables

One session on Monday afternoon particularly resonated with us: Remote Monitoring in Heart Failure — implants, wearables and patient management.

A recurring theme from clinicians was straightforward: wearables are generating increasing volumes of data, but translating those signals into treatment decisions remains difficult.

Continuous monitoring offers valuable insights, yet many physicians remain cautious about relying on these signals to guide medication adjustments or clinical interventions. In heart failure care, where therapeutic decisions can have significant consequences, data alone is not enough — it must be reliable, interpretable, and clinically validated.

Artificial intelligence is often proposed as a way to bridge this gap by identifying meaningful patterns within large datasets. However, speakers emphasized that robust clinical validation of AI-driven insights remains limited, and significant work is still needed before these approaches can fully integrate into routine care.

Growing Interest in Pressure-Based Monitoring

Another strong signal emerging from the conference was the increasing focus on pressure-based monitoring as a way to detect congestion earlier and intervene before symptoms worsen.

Several experts compared this evolution to what happened in diabetes management: once reliable physiological monitoring became available, it enabled more proactive and structured disease management.

In heart failure, early detection of congestion could similarly help reduce hospitalizations and improve patient outcomes.

At the same time, healthcare systems are facing a structural challenge: the number of heart failure specialists remains limited, while the number of patients continues to grow.

This reality reinforces the need for monitoring tools that support simpler care pathways and greater patient autonomy, allowing patients to manage certain aspects of their condition under clear clinical protocols.

Beyond Sensors: Integrating Data Into Care Pathways

Across the ecosystem, many technologies are emerging — ranging from wearables to implantable devices — each attempting to capture different physiological signals.

Yet one challenge remains central: transforming physiological measurements into actionable guidance that fits into everyday clinical practice.

The discussions at THT repeatedly highlighted that successful remote monitoring solutions will likely combine multiple physiological inputs with well-defined care protocols that determine when and how to act on alerts.

Without this link between signals and clinical decision-making, even sophisticated monitoring technologies risk remaining underutilized.

A Turning Point for Heart Failure Monitoring

The conversations at THT 2026 reinforced a growing consensus across the field.

Remote monitoring in heart failure is entering a new phase — one that moves beyond data collection toward clinically actionable and scalable care models.

At CardiaMetrics, these discussions strongly resonate with the vision that drives our work: providing reliable physiological insights that can support earlier detection of congestion and more proactive patient management.

As heart failure prevalence continues to rise worldwide, innovations that translate physiological signals into meaningful clinical decisions will be essential to supporting clinicians, empowering patients, and improving long-term outcomes.

We are proud to announce that CardiaMetrics has successfully completed its second fundraising round, securing €1.7 million in new investment to fuel the next phase of our development. This milestone reflects growing confidence in our vision to transform the management of heart failure through advanced remote monitoring technologies — and signals a strong step forward in our journey since our first successful €300K seed round in 2024.

Building on Our Early Progress

A little over a year ago, we shared the exciting news of our first funding round, in which we raised €300,000 from private investors and leading cardiologists who recognized the unique value of our solution for bridging the gap between non-invasive telemonitoring approaches and implantable pressure sensors.

That funding enabled us to lay strong foundations — accelerating key strategic hires and preparing our first clinical studies in collaboration with the Caen University Hospital (CHU de Caen) to validate clinical safety and kick off our AI strategy.

Today, with €2M raised, we are ready to accelerate even further.

What This Funding Enables

This latest round will support several high-impact strategic pillars:

We have also established a Strategic Advisory Committee, bringing together experienced clinicians and industry leaders to guide our clinical strategy and reinforce our market positioning moving forward.

Strengthening Our Vision and Market Opportunity

Since our first fundraising announcement, CardiaMetrics has continued to assert its position in the heart failure telemonitoring landscape by combining cutting-edge sensing technologies, AI capabilities, and a deep clinical partnership model (10 clinical centers will onboard in our next clinical study). This new funding reflects investor confidence in our mission to provide clinically relevant, home-based telemetry that meaningfully impacts patient care.

With heart failure affecting millions worldwide and health systems seeking solutions that both improve outcomes and optimize costs, CardiaMetrics is uniquely positioned to help shift care paradigms from reactive to proactive, preventive strategies.

What’s Next

We remain deeply committed to our clinical milestones, regulatory pathway, and expansion goals — with ambitious plans to scale our solution across Europe and USA.

Stay tuned as we continue to publish updates on our clinical progress, scientific collaborations, and technology development throughout 2026 and beyond.

CardiaMetrics is proud to announce that our first scientific results will be presented at Technology and Heart Failure Therapeutics (THT) in Boston (Home Page | THT 2026), one of the world’s leading conferences dedicated to breakthrough technologies in heart failure care.

Our abstract, entitled:

“Cutaneous device and machine learning could estimate pulmonary capillary wedge pressure in patients with heart failure”

has been selected for presentation during:

HF Insight – First-in-Man / Early Feasibility Studies Abstracts Session III
📅 Wednesday, March 4
🕘 9:15 AM – 10:21 AM (ET)
📍 Room: Ensemble C-D | Level 2
🎤 Presentation by Rémi Sabatier at 10:10 AM

A Major Scientific Milestone

This presentation represents the first peer-reviewed scientific outcome from CardiaMetrics to be showcased on an international stage.

Being selected for THT, a best-in-class conference gathering global leaders in cardiovascular innovation, is a strong validation of our technology and scientific approach. It reflects growing recognition from the clinical and research community of our work in reconstructing intracardiac pressures using machine learning.

Advancing Low-Invasive Hemodynamic Monitoring

Our study demonstrates that a low-invasive cutaneous device combined with advanced machine learning algorithms can estimate pulmonary capillary wedge pressure (PCWP), a critical hemodynamic parameter in the management of heart failure patients.

Accurate assessment of intracardiac pressure typically requires invasive procedures or heavily implantable sensors. Our approach aims to provide a scalable, data-driven alternative capable of supporting earlier detection of decompensation and more proactive disease management.

This research represents an important step toward bridging the gap between traditional remote monitoring solutions and low-implantable pressure sensors.

Built on Clinical Research with CHU de Caen

These results stem from the clinical study we initiated in collaboration with CHU de Caen. This early feasibility study laid the foundation for validating our technology.

The data generated through this collaboration enabled the development and validation of our machine learning models for reconstructing intracardiac pressure low-invasively.

Read previous article

Scientific Recognition of Our Machine Learning Approach

The acceptance of our abstract at THT underscores the scientific community’s recognition of our physiology-based machine learning methodology. Reconstructing intracardiac pressure from non-invasive signals represents a significant technological challenge — and a meaningful opportunity to transform heart failure management.

This milestone reflects the dedication of our expanding team, the strength of our clinical partnerships, and the continued trust of our investors and collaborators.

Looking Ahead

Presenting at THT Boston marks the beginning of CardiaMetrics’ international scientific visibility. We look forward to engaging with clinicians, researchers, and industry leaders to further advance innovation in scalable, low-invasive hemodynamic monitoring.

This achievement reinforces our mission: to redefine heart failure care through intelligent, accessible, and clinically validated remote monitoring solutions.

At the beginning of the year, there is no better place to take the pulse of cardiology innovation than JESFC 2026 (Journées Européennes de la Société Française de Cardiologie).
As our first congress of the year, CardiaMetrics is proud to attend this key scientific and clinical event, which brings together cardiologists, researchers, healthcare professionals, and industry players from across Europe.

Starting the Year by Feeling the Trends

JESFC is more than a congress — it is a barometer of emerging trends in cardiovascular care. Attending the event allows us to:

• Stay closely connected to the latest clinical research and guidelines in cardiology

• Understand evolving needs and practices in heart failure management

• Identify scientific and technological signals that will shape the year ahead

For CardiaMetrics, this early-year presence is a strategic way to kick off 2026 with clarity, alignment, and ambition.

Meeting Physicians and Strengthening Clinical Dialogue

As a medtech company developing a home-based remote monitoring solution for heart failure patients, close collaboration with clinicians is essential.
JESFC provides a unique opportunity to:

• Exchange directly with cardiologists and heart failure specialists

• Discuss real-world clinical challenges and expectations

• Share our vision and gather feedback to continuously refine our solution

These conversations are at the core of our approach: designing technology that truly supports clinical decision-making and patient care.

Connecting with Partners Across the Ecosystem

Beyond clinical discussions, JESFC is also a key meeting point for:

• Academic and hospital partners

• Medtech and digital health innovators

• Institutional and industrial stakeholders

By engaging with this ecosystem, we aim to build strong, long-term partnerships that accelerate clinical validation, adoption, and impact.

A Strong Start for a Year of Momentum

Following major milestones for CardiaMetrics — including team growth, the launch of our first clinical trial, and continued technological development — JESFC 2026 marks an important moment to align science, innovation, and collaboration from the very start of the year.

We look forward to insightful discussions, inspiring research, and meaningful connections at JESFC 2026.

📍 See you at JESFC 2026
🔗 https://www.sfcardio.fr/congres-detail/jesfc-2026/

Let’s start the year by advancing cardiology together.

On February 4–5, 2026, Grenoble will become the meeting point for those shaping the technologies of tomorrow.
On this occasion, CardiaMetrics will be attending Tech&Fest, the must-attend tech event of the start of the year, bringing together startups, industry leaders, researchers, investors, and decision-makers around a shared ambition: to build innovation that is useful, responsible, and sovereign.

An Edition Focused on Sovereignty

For its 3rd edition, Tech&Fest has chosen a strong central theme: “Sovereignty.”
Economic, industrial, energy, and digital sovereignty — but also health sovereignty.

A topic that strongly resonates with CardiaMetrics’ mission:
👉 to contribute to a more effective and sustainable management of heart failure, through innovative medical technologies developed in Europe and designed to address real healthcare system challenges.

Why Tech&Fest Is a Key Event for CardiaMetrics

Participating in Tech&Fest means much more than showcasing innovation. It means engaging with a committed, multidisciplinary ecosystem.

Over two days, the program includes:

• 💡 More than 250 high-level speakers sharing their insights on strategic topics such as AI, cybersecurity, quantum technologies — and of course medtech, at the heart of healthcare transformation.

• 🔎 Four immersive thematic areas and over 350 exhibitors — startups, SMEs, and large corporations — ready to showcase the innovations shaping our future.

• 🌍 A Decarbonation Village, highlighting the need for technological progress aligned with environmental responsibility.

• 🤝 More than 20,000 B2B participants: executives, researchers, entrepreneurs, investors — with many dedicated networking opportunities.

Advancing Healthcare, Together

At CardiaMetrics, we firmly believe that major healthcare breakthroughs emerge from collaboration — between engineering, clinical practice, research, and industry.
Tech&Fest provides the ideal environment to challenge ideas, share experiences, and build synergies around a common goal: putting technology at the service of patients and healthcare professionals.

We look forward to meeting those who, like us, believe in rigorous, ethical innovation focused on real-world impact.

📍 Join us on February 4–5, 2026, in Grenoble
🔗 https://www.tech-fest.fr/

Will you be there?

On November 27, 2025, our team attended the second edition of the forum “Santé pour tous : IA & données de santé”, organized by the University of Caen Normandy / Caen Normandie Development.

This event brought together students, researchers, start-ups, clinicians, and project leaders around health innovation at the crossroads of artificial intelligence, clinical data, and research.

For CardiaMetrics, as a key player in remote monitoring for heart failure and connected health, it was an excellent opportunity to compare our vision with regional trends, expand our network, and contribute to the discussion on the responsible use of health data.